• Ongoing pressure on the conventional pesticides market, which is subject to increased scrutiny and regulatory pressures contributing to significant disruption.

• Increasing time and cost of bringing new conventional chemical products to market: 10-12 years and around $300 million.

• Significantly lower costs of bringing biopesticides to market – around $25million.

• Major product withdrawals across all segments of the conventional crop protection industry are having a significant impact on growers leaving them with lower yields and declining productivity.

• Ownership of the patents behind the Sustaine encapsulation technology.

• Proven efficacy with strong commercial validation by farmers and our partners.

• Scope to exploit the core technologies beyond existing markets and products.

• Eden’s products serve as sustainable alternatives to conventional chemicals without limitations such as residue limits, pest resistance, long pre-harvest intervals and field re-entry periods or increasing restrictions on use such as the proposed microplastics legislation.

• Residue-free crops command a higher value and have a significant commercial advantage in the valuable export markets.

• Solid commercial pipeline.

• Regulatory clearance for product sales across multiple countries with applications pending in a number of countries.

• Commercial and collaborative relationships with strong industry partners.

• Significant investment in commercialisation by key partners.

• Applications on key crops increasing with further approvals and label extensions.

• Sales on four continents today – expected to expand to six in the coming years.

• Strong Board and management team.

• Lykele van der Broek appointed as Non-Executive Director and Chairman – former Board member and COO of Bayer CropScience.

• Wealth of experience in the agriculture, consumer products and animal health sectors globally.

• In-house expertise in formulation chemistry and biology.

• Outsourcing of some functions to maintain a flexible, low overheard base.

• Increased product sales volume.

• Significant investment by key partners.

• Robust balance sheet.

* before non-cash share based payment charge, depreciation and amortisation